SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Nov 30, 2017

AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: Nov. 30, 2017 · CIK: 0001385818 · Accession: 0001213900-17-012805

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-221735

Date
November 30, 2017
Author
AYTU BIOSCIENCE
Form
CORRESP
Company
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)

Letter

AYTU BIOSCIENCE, INC.

373 Inverness Parkway, Suite 206

Englewood, CO 80112

November 30, 2017

Via Edgar

Division of Corporate Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Christine Westbrook

Re: Aytu Bioscience, Inc.

Registration Statement on Form S-3

Filed November 22, 2017

File No. 333-221735

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Aytu BioScience, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Daylight Time, on Friday, December 1, 2017, or as soon thereafter as possible.

The Company acknowledges the following:

· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
AYTU BIOSCIENCE,
INC.

Show Raw Text
CORRESP
1
filename1.htm

AYTU BIOSCIENCE, INC.

373 Inverness Parkway, Suite 206

Englewood, CO 80112

November 30, 2017

Via Edgar

Division of Corporate Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention:  Christine Westbrook

Re:   Aytu Bioscience, Inc.

    Registration Statement on Form S-3

    Filed November 22, 2017

    File No. 333-221735

Ladies and Gentlemen:

Pursuant to Rule
461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Aytu BioScience, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become
effective at 4:30 p.m., Eastern Daylight Time, on Friday, December 1, 2017, or as soon thereafter as possible.

The Company acknowledges
the following:

 · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose
the Commission from taking any action with respect to the filing;

 · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does
not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.

    Very truly yours,

    	AYTU BIOSCIENCE,
INC.

    By:
    /s/ Joshua R. Disbrow

    Joshua R. Disbrow
Chief Executive Officer